A Study of Golimumab in Participants With Active Ankylosing Spondylitis

PHASE3CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

September 3, 2014

Primary Completion Date

December 15, 2015

Study Completion Date

October 11, 2016

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Placebo

Participants will receive matching placebo.

DRUG

Golimumab

Participants will receive 2mg/kg of intravenous infusions of golimumab .

Trial Locations (45)

Unknown

Glendale

Mesa

La Palma

Granger

St Louis

Orchard Park

Salisbury

Middleburg Heights

Duncansville

Austin

Houston

Maroochydore

St. John's

Burlington

Trois-Rivières

Bad Doberan

Berlin

Erfurt

Hamburg

Planegg

Ratingen

Zerbst

Chihuahua City

Bydgoszcz

Bytom

Nadarzyn

Nowa Sól

Poznan

Warsaw

Moscow

Saint Petersburg

Saratov

Smolensk

Tver'

Ansan

Daegu

Gwangju

Seongdong-Gu

Seoul

Chernihiv

Dnipropetrovsk

Kyiv

Odesa

Vinnytsia

Zaporizhzhia

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02186873 - A Study of Golimumab in Participants With Active Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter